醋酸甲地孕酮联合盐酸二甲双胍作为早期子宫内膜样腺癌和子宫内膜非典型增生患者保留生育功能治疗:一项前瞻性研究OA北大核心CSTPCDMEDLINE
Megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early-stage endometrial adenocarcinoma:a prospective study
目的 评估在子宫内膜不典型增生(AEH)或早期1级子宫内膜样腺癌(G1 EAC)患者中,使用醋酸甲地孕酮(MA)联合二甲双胍作为保留生育功能治疗的疗效和复发率,分析治疗后子宫内膜中IGFBP-rP1、p-AMPK和p-Akt的表达变化.方法 前瞻性招募60名年龄在20～42岁之间的AEH和/或病灶局限于子宫内膜的1级EAC患者.患者被随机分为MA组(n=30)和MA加二甲双胍组(n=30).对照组患者接受MA(口服160 mg,2次/d)治疗,联合组患者在口服MA治疗的基础上加用二甲双胍(口服850 mg,2次/d),治疗持续至少6个月,必要时可延长至12个月以达到完全缓解(CR),并每3个月进行一次随访宫腔镜检查和刮宫术.对于达到CR的患者,通过免疫组织化学方法检测子宫内膜组织中IGFBP-rP1、p-Akt和p-AMPK的表达.结果 共有58名患者完成了治疗.在治疗第9个月时,联合治疗组中23例(76.7%)患者达到了CR;对照组中20例(71.4%)患者达到了CR,另外两例患者在将治疗改为二甲双胍联合MA治疗后也达到了CR.联合治疗组的复发率为22.7%,对照组为30.0%.对照组10名患者(35.7%)体质量增加5.7±6.1 kg,而在联合组患者体质量变化没有统计学意义.与对照组相比,联合治疗组子宫内膜组织中IGFBP-rP1和p-AMPK表达增加,p-Akt表达降低.结论 MA和二甲双胍联合治疗可作为1级IA期EAC和AEH的保留生育功能治疗的有效方法,二甲双胍辅助治疗可以控制由MA引起的体质量增加,增加子宫内膜组织中IGFBP-rP1和p-AMPK的表达,同时抑制p-Akt的表达.该疗法在早期EAC和AEH治疗中的作用值得进一步研究.
Objective To evaluate the efficacy of medroxyprogesterone acetate(MA)plus metformin as the primary fertility-sparing treatment for atypical endometrial hyperplasia(AEH)and early-stage grade 1 endometrial adenocarcinoma(G1 EAC)and the recurrence rate after treatment.Methods Sixty patients(aged 20-42 years)with AEH and/or grade 1 EAC limited to the endometrium were enrolled prospectively and randomized into two groups(n=30)to receive oral MA treatment at the daily dose of 160 mg(control)or MA plus oral metformin(850 mg,twice a day)for at least 6 months.The treatment could extend to 12 months until a complete response(CR)was achieved,and follow-up hysteroscopy and curettage were performed every 3 months.For all the patients who achieved CR,endometrial expressions of IGFBP-rP1,p-Akt and p-AMPK were detected immunohistochemically.Results A total of 58 patients completed the treatment.After 9 months of treatment,23(76.7%)patients in the combined treatment group and 20(71.4%)in the control group achieved CR;two patients in the control group achieved CR after converting to the combined treatment.The recurrence rate did not differ significantly between the control group and combined treatment group(30.0%vs 22.7%,P>0.05).Ten(35.7%)patients in the control group experienced significant weight gain of 5.7±6.1 kg,while none of the patients receiving the combined treatment exhibited significant body weight changes.Compared with the control group,the patients receiving the combined treatment showed enhanced endometrial expressions of IGFBP-rP1 and p-AMPK with lowered p-Akt expression.Conclusion Metformin combined with MA may provide an effective option for fertility-sparing treatment of AEH and grade 1 stage IA EAC,and the clinical benefits of metformin for controlling MA-induced weight gain and promoting endometrial expressions of IGFBP-rP1 and p-AMPK while inhibiting p-Akt expression warrants further study.
王圆圆;来天娇;褚丹霞;白晶;严淑萍;秦海霞;郭瑞霞
新乡医学院第一附属医院妇科一病区,河南 卫辉 453100||郑州大学第一附属医院妇科一病区,河南 郑州 450052郑州大学第一附属医院妇科一病区,河南 郑州 450052郑州大学第一附属医院妇科一病区,河南 郑州 450052郑州大学第一附属医院妇科一病区,河南 郑州 450052郑州大学第一附属医院妇科一病区,河南 郑州 450052新乡医学院第一附属医院妇科一病区,河南 卫辉 453100郑州大学第一附属医院妇科一病区,河南 郑州 450052
子宫内膜样腺癌盐酸二甲双胍子宫内膜非典型增生保留生育功能治疗醋酸甲地孕酮胰岛素样生长因子结合蛋白相关蛋白1
endormetrial adenocarcinomametforminatypical endometrial hyperplasiafertility-sparing treatmentmegestrol acetateinsulin-like growth factor binding protein-related protein 1
《南方医科大学学报》 2024 (11)
2055-2062,8
Supported by Supported by National Natural Science Program of China(31670844)Central Plains Thousand Talents Program(ZYQR200810107),and Outstanding Talents of Science and Technology Innovation Program of Henan Province(2018JR0004).Corresponding authors:GUO Ruixia,E-mail:grxcdxzzu@163.com. 国家自然科学基金(31670844)中原英才千人计划项目(ZYQR200810107)河南省科技创新计划杰出人才项目(2018JR0004)
评论